Global Infectious Disease Molecular Diagnostics Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

The "Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Technology (PCR, ISH, INAAT), By End-use, By Application, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global infectious disease molecular diagnostics market size is expected to reach USD 40.8 billion by 2028, according to a new report by the publisher. The market is estimated to expand at a CAGR of 3.0% from 2020 to 2028. The market is driven by the introduction of technologically advanced products and an increase in demand for molecular diagnostics in PoC settings.

Rapid technological advancements with portability, accurate results, and cost-effectiveness are anticipated to serve as crucial drivers of the market for infectious disease molecular diagnostics. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Key players are updating their product portfolio for PCR instruments with increased R&D initiatives for developing novel kits to target emerging diseases or by entering into agreements with other kit manufacturing companies.

Technologies such as INAAT, mass spectroscopy, and ISH are advanced and have a low false-positive rate as compared to other traditional diagnostic tests. Advantages such as the cost-effectiveness and user-friendliness of this technology and the accuracy offered are estimated to increase the adoption of this technology.

The use of molecular diagnostics in research institutes is increasing. The use of techniques such as PCR, western blotting, and southern blotting is becoming common. Moreover, the spread of SARS-CoV-2 infection globally has led to an increase in research funding by governments as well as diagnostic companies to search for innovative molecular diagnostics.

Molecular diagnostics deliver effective and accurate results. Moreover, these tests enable the early detection of diseases, maintaining a low threat of substitutes. However, the high prices of these tests are expected to encourage patients to shift to external substitutes. Moreover, for the detection of newer infections such as SARS-CoV-2, the rate of internal substitution is high, which boosts competitive rivalry.

Infectious Disease Molecular Diagnostics Market Report Highlights

• The reagent segment is expected to exhibit the fastest growth rate attributable to increased adoption
• The growing geriatric population in Asian countries, such as Japan and China, with high untapped opportunities is expected to drive the market for infectious disease molecular diagnostics in the region during the forecast period
• The In Situ Hybridization (ISH) segment is anticipated to witness the fastest growth rate owing to high sensitivity and lower complexity
• The high growth rate of the market for infectious disease molecular diagnostics in the Asia Pacific can be attributed to increased access to healthcare in the developing nations

Market Dynamics

Drivers

• Increase in geriatric population
• Introduction of technologically advanced products
• Increase in demand for point-of-care Daignostics
• Growing prevalence of target diseases
• Increasing external funding for R&D
• Outbreak of COVID-19

Restraints

• Presence of ambiguous regulatory framework
• High prices of Infectious Disease Molecular Diagnostics tests

Companies Mentioned

• Abbott
• Becton, Dickinson and Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Danaher Corporation
• Hologic, Inc. (Gen Probe)
• Illumina, Inc.
• GRIFOLs S.A.
• Qiagen
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers
• Sysmex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/xh7t4h

View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005674/en/